Eagle Asset Management Inc Sage Therapeutics, Inc. Transaction History

Eagle Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 07, 2020	SELL	$60.18 - $154.77 $28.9 Million - $74.3 Million	-480,181 Closed	0 $0
Q3 2019 Nov 04, 2019	SELL	$140.29 - $189.96 $8.06 Million - $10.9 Million	-57,469 Reduced 10.69%	480,181 $67.4 Million
Q2 2019 Aug 05, 2019	BUY	$157.85 - $183.09 $312,227 - $362,152	1,978 Added 0.37%	537,650 $98.4 Million
Q1 2019 May 01, 2019	SELL	$89.33 - $163.65 $9.98 Million - $18.3 Million	-111,670 Reduced 17.25%	535,672 $85.2 Million
Q4 2018 Feb 11, 2019	SELL	$81.94 - $139.71 $546,703 - $932,145	-6,672 Reduced 1.02%	647,342 $62 Million
Q3 2018 Nov 08, 2018	BUY	$138.11 - $169.04 $9.81 Million - $12 Million	71,032 Added 12.18%	654,014 $92.4 Million
Q2 2018 Aug 07, 2018	SELL	$140.36 - $175.76 $4.52 Million - $5.66 Million	-32,231 Reduced 5.24%	582,982 $91.3 Million
Q1 2018 May 09, 2018	SELL	$152.15 - $192.33 $580,452 - $733,738	-3,815 Reduced 0.62%	615,213 $99.1 Million
Q4 2017 Feb 09, 2018	SELL	$60.72 - $167.34 $485,942 - $1.34 Million	-8,003 Reduced 1.28%	619,028 $102 Million
Q3 2017 Nov 09, 2017	BUY	$61.4 - $88.52 $38.5 Million - $55.5 Million	627,031	627,031 $39.7 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $330M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Eagle Asset Management Inc with notifications on news.